news
Sava raises $36M for glucose microsensor, partners with Ascensia
Sava secured $36 million in Series A funding, led by Ascensia Diabetes Care, to advance its continuous glucose microsensor toward a European launch. The partnership aims to bring Sava's needle-free device to market, potentially disrupting traditional fingerstick blood glucose monitoring.
Sava secured $36 million in Series A funding, led by Ascensia Diabetes Care, to advance its continuous glucose microsensor toward a European launch. The partnership aims to bring Sava's needle-free device to market, potentially disrupting traditional fingerstick blood glucose monitoring.
The architecture take
So a company that sells fingerstick glucose meters just invested $36 million into a needle-free glucose sensor. I'm not saying it's ironic, but I am saying to watch the money. The goal here isn't just to make monitoring blood sugar easier for people with diabetes; it’s about making real-time metabolic data accessible to anyone. Ascensia isn't just funding a competitor; they’re buying a seat at the table for the next generation of health tech. We're moving from reactive testing to proactive, continuous feedback loops. Think beyond diet plans and into immediate, personalized biofeedback that influences everything from sleep to stress. Your body's internal state—your blood sugar load—will be visible in real-time, all the time. That changes how people eat, move, and think about their energy capacity.